UNSPSC 51263165: Levobunolol hydrochloride

This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C17H25NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O90S49LDHH, chemically known as 1(2h)-naphthalenone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, hydrochloride, (-)- but more generally known as levobunolol hydrochloride, which bears US NIH Compound Identifier 34060.

UNSPSC 51263165 Levobunolol hydrochloride is a Commodity code for a specific pharmaceutical product, but the recent state and local contracting activity associated with this code does not reflect procurement of levobunolol hydrochloride or related ophthalmic medications. The single recent opportunity tagged to this code—Seminole County, Florida's IFB 60459723LAS for naloxone and drug deactivation systems—falls outside the nominal scope of the code and does not constitute a representative use case for business development purposes. The mismatch suggests either a data-entry error in the opportunity's UNSPSC coding or a fundamental misalignment between the code's pharmaceutical scope and the jurisdiction's actual procurement need.

No recent state and local opportunities reflecting the true scope of UNSPSC 51263165 (levobunolol hydrochloride procurement) appear in the available record. Levobunolol hydrochloride is a beta-blocker ophthalmic preparation used to manage intraocular pressure in glaucoma and ocular hypertension; procurement under this code would typically surface through state health departments, public health clinics, correctional-facility medical services, or municipal public-health agencies purchasing ophthalmic medications for patient care or inventory. The absence of relevant recent solicitations suggests either minimal state and local demand for this specific pharmaceutical formulation, concentration of such purchases through bulk cooperative purchasing or standing-supply agreements that do not trigger individual RFP or IFB notices, or routing of ophthalmic medication procurement through higher-level pharmaceutical commodity codes that aggregate multiple drug formulations rather than individual active ingredients.